OR WAIT null SECS
March 20, 2026
The FDA approved higher-dose semaglutide (7.2 mg) in 54 days under its new priority voucher program, signaling faster reviews for drug developers.
March 19, 2026
FDA's March 2026 draft guidance outlines a validation framework for non-animal drug testing methods, signaling a shift in nonclinical submission expectations.
March 18, 2026
Industry experts explain how incorporating sustainability into the early development phase creates greener pharmaceutical manufacturing.
March 16, 2026
The FDA will evaluate tildrakizumab-asmn for psoriatic arthritis. A 2026 decision is expected based on Phase III clinical trial data.
March 13, 2026
This week, the industry experienced accelerated digital transformation, regulatory evolution, and a strategic shift toward complex, patient-centric modalities.
March 11, 2026
This article reviews the use of Raman spectroscopy in a series of case studies to quickly identify the iron oxide compound(s), including magnetite and hematite, on the surface of representative endcaps or piping spool pieces. The article also provides a strategy using a detergent additive to remove magnetite without performing costly electro- or mechanical polishing.
March 09, 2026
The 2mg/kg every-4-weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable with an enzyme replacement therapy has been approved in Europe.
March 06, 2026
Developments across the sector highlight a period of rapid acceleration and structural modernization.
March 04, 2026
The author discusses analytical techniques associated with cleaning and disinfection; cleanroom operation; packaging component preparation; water-for-injection production; sterile product preparation; and aseptic filling, stoppering, and sealing.
February 27, 2026
The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a treatment for the ultra-rare disease, fibrodysplasia ossificans progressiva.